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Background: The Burden of Obstructive Lung Disease study showed that in Germany, to confirm
the diagnosis of chronic obstructive lung disease (COPD) in one subject, eight people 40 years
of age have to be screened. The number-needed-to-screen (NNS) increased to 18 for identi-
fying a patient with COPD GOLD stage II. These high numbers limit the cost-effectiveness
of COPD screening by population spirometry. We investigated in a primary care setting whether
using two simple questions regarding smoking status and presence of cough and/or dyspnea
may help to preselect patients for proper diagnosis of COPD.
Methods: A total of 1088 patients aged 40 yrs without a history of chronic lung disease, who
were either current or ex-smokers and complained of cough and/or dyspnea, were examined
by respiratory physicians. Spirometry was carried out to confirm COPD diagnosis and severity.
Results: A total of 61.6% of patients were male. Mean smoking history was 31.8 pack-yrs. In 516
patients (47.4%), a diagnosis of COPD was confirmed. Among these, 379 (34.8% of total) had at
least GOLD stage II COPD, while 89 (8.2% of total) had advanced disease (GOLD stages III/IV).
COPD prevalence was significantly associated with age and the extent of cigarette smoke
exposure.
Conclusions: Two questions regarding smoking status and presence of cough and/or dyspnea
enabled general practitioners to select patients at risk for COPD for subsequent spirometry.
This preselection reduced the NNS to 2.1 for identifying a COPD patient, and to 2.9 for iden-
tifying a patient of at least GOLD stage II.
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Chronic obstructive pulmonary disease (COPD) is a major
health problem that causes disability and premature death.
It was the fifth leading cause of death worldwide in 2001,1
fourth in 2004, and is expected to advance to position three
by the year 2030 (WHO World Health Statistics Report 2008;
http://www.who.int/whosis/whostat/en/), presumably
reflecting the continued use of tobacco and the ageing of
the world’s population.2 COPD is a chronically progressive
disease characterized by an increasing loss of lung func-
tion.3 No therapeutic intervention is able to reverse loss of
lung function once it has occurred. The Lung Health Study
demonstrated that smoking cessation programs at an early
stage of COPD can significantly slow the deleterious decline
in lung function seen in COPD patients who continue to
smoke.4 Therefore, in order to prevent development of
severe COPD, it is critical to identify smokers at the earliest
possible stage of the disease and offer them assistance to
stop smoking.
Large population-based studies like the U.S. National
Health and Nutrition Examination Survey III (NHANES-III) or
the Health Survey for England (HSE) demonstrated that
60e80% of subjects with COPD identified by mass spirom-
etry were undiagnosed, and even among subjects with
more severe airflow limitation, almost one half had no
previous diagnosis of any obstructive lung disease.5,6 This
under-diagnosis or delay of COPD diagnosis may either be
a consequence of the patients’ gradual adaptation to
a decreasing lung function7 or of healthcare givers being
unaware of e or not responding to e the symptoms of the
patient. Therefore, population screening programs may
represent a useful tool to early identification of COPD
patients who would otherwise remain unrecognized e and
hence untreated e for years. However, given the budgetary
constraints of public health systems, the feasibility of mass
screening an unselected adult population using spirometry
is questionable, since an unreasonably large number of
spirometry tests have to be carried out in order to identify
a patient with COPD: in the German subpopulation of the
Burden of Obstructive Lung Disease (BOLD) initiative, e.g.,
a COPD prevalence of 13.2% was found, indicating that
eight subjects have to be tested by spirometry for identi-
fying a single case with COPD.2,8
In the current study, we demonstrate that by using two
simple questions regarding smoking status and presence of
cough and/or dyspnea it is possible to preselect a patient
group with a higher prevalence of COPD and thereby to
substantially reduce the NNS for identifying a COPD case.
Materials and methods
This COPD case-finding study was carried out as a prospec-
tive pragmatic trial in a clinical practice setting that
involved pulmonologists and locally associated primary care
physician (PCP) in both urban and rural areas of Germany.
Six hundred eighty-four PCPs and 137 respiratory physicians
participated. Participating PCPs were requested to screen
consecutive unselected patients of both sexes and aged
40 yrs with no previous diagnosis of lung disease who
visited their practice by asking them two entry questions:(1) Do you currently or did you ever smoke?
(2) Do you regularly suffer from cough and/or
breathlessness?
Patients that affirmed both questions were selected and
the physician filled out a 10-item questionnaire.
Questionnaire
The questionnaire was previously developed by selecting
items from a large collection of questions that were most
predictive of a diagnosis of COPD and independently were
significantly associated with COPD in a study using multi-
variate logistic analysis.9 Eight items were identified that
showed a significant association with COPD, including age;
pack-years of cigarettes smoked; body mass index (BMI);
cough affected by weather conditions; coughing up phlegm
in the absence of a cold; morning phlegm; wheeze
frequency; and history of allergy. Since for calculation of
BMI (size and weight) and pack-years (cigarettes smoked
and number of years smoked) the answers to two questions
were required, the questionnaire comprised 10 questions.
Based on the scores assigned to each possible answer in the
questionnaire, a COPD risk score ranging from 0 to 38 was
calculated for each patient (Table 1).
All patients for whom questionnaires were filled out
were, independently of their COPD risk score referred to
the locally associated pulmonologist to confirm a clinical
diagnosis of COPD and e if applicable e classify patients
according to the severity stage of the disease. The pulmo-
nary specialists were instructed to follow the recommen-
dations provided by the GOLD guideline (www.goldcopd.
com),10 but no further instructions were given in order to
reflect as closely as possible usual care. Judgement of
reversibility of airway obstruction and severity classifica-
tion according to GOLD requires post-bronchodilator
pulmonary function testing. FEV1 (L), FEV1% of standard
value, and FVC were recorded, but no specifications were
made regarding the spirometer to be used. The dependence
of COPD prevalence and GOLD stage distribution on COPD
risk score and individual questionnaire items was tested.
Analysis
The numbers of patients with severe and very severe COPD
(GOLD IIIþ IV) were combined for the purpose of this
analysis. In the case of missing information regarding COPD
diagnosis (<1% of all validation questionnaires), it was
conservatively assumed that no COPD was present in order
to avoid overestimation of COPD prevalence. Numbers-
needed-to-screen (NNS) were calculated as the reciprocal
values of prevalence.
All questionnaire data were analysed according to the
usual standard procedures for descriptive analyses of
epidemiological studies. To test for statistical significance,
the chi-square test was applied to nominal data and the
ManteleHaenszel test to ordinal scales. For the exploratory
examination of correlations/associations between inde-
pendent factors as derived from the questionnaire and
COPD severity (GOLD stage), analyses were performed with
the help of the General Linear Model (GLM) procedure.
Table 1 Questionnaire items.
Item Categories Score
1 What is your age? 40e49 yrs 0 Points
50e59 yrs 4 Points
60e69 yrs 8 Points
70 yrs or older 10 Points
2 How many cigarettes do you or did you smoke per day? Pack-years:
3 For how many years in total did you smoke? 0e14 0 Points
15e24 2 Points
Pack-years: cigarettes smoked per day * years of smoking/20 25e49 3 Points
50 7 Points
4 What is your weight (kg) Body mass index:
5 What is your height (m) <25.4 5 Points
25.4e29.7 1 Point
Body mass index: weight/(height)2 >29.7 0 Points
6 Is your cough affected by weather conditions? Yes 3 Points
No 0 Points
No cough 0 Points
7 Do you cough up phlegm even if you do not have a cold? Yes 3 Points
No 0 Points
8 Do you cough up phlegm after
getting up in the morning?
Yes 0 Points
No 3 Points
9 How often do you have a wheezing noise when breathing? Never 0 Points
Occasionally or more 4 Points
10 Do you or did you suffer from allergy? Yes 0 Points
No 3 Points
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Questionnaires were filled out for 2276 patients aged 40
years who were identified by their PCPs as being current or
ex-smokers and complaining of cough and/or dyspnea. All
patients were encouraged to see a local pulmonologist in
order to be tested for COPD. A total of 1282 patients
(56.3%) followed this recommendation and were examined
by specialists for validation of a COPD diagnosis and
severity classification. Combined patient questionnaires
and GOLD stage data were available for 1088 patients
(47.8%) which represent the validation population analysed
in this study. Demographic and biometric data are shown in
Table 2. The 194 participants with missing patient ques-
tionnaires did not significantly differ from the 1088 patients
analysed with respect to gender distribution and age.
Mean FEV1 within the validation population was
2.42 0.87 L, corresponding to 80.4 22.2% of the stan-
dard value, while mean FEV1/FVC was 82.5 18.4%. Thus,
average pulmonary function of the patients was within the
normal range. Nevertheless, in 516 of the 1088 patients
(47.4%), a COPD diagnosis was confirmed by a pulmonologist
(Fig. 1). Among these, 137 (12.6%) were in GOLD stage I, 290
(26.7%) in GOLD stage II, and 89 (8.2%) in GOLD stages III or
IV. These numbers corresponded to a NNS of 2.1 for iden-
tifying a COPD patient or a NNS of 2.9 for identifying
a patient with COPD of at least GOLD stage II. COPD was
excluded in 433 patients (39.8%), while in the remaining 139patients (12.8%) a COPD diagnosis could neither be
confirmed nor excluded upon the first specialist visit.
The mean questionnaire-derived COPD risk score within
the validation population was 20.1 6.1 points. Based on
the distribution of patients over the range of risk score
values, scores of 18 and 23 were arbitrarily selected as cut-
off values to divide the validation population into three
groups of approximately equal size with an assumed low
(risk score 0e17; nZ 359), intermediate (risk score 18e22;
nZ 361), and high (risk score 23e38; nZ 362) risk of COPD.
The prevalence of specialist-confirmed COPD and GOLD
stage distribution according to the risk categories are also
included in Fig. 1: Both prevalence and severity of COPD
increased with increasing risk category, but even in the
presumed low-risk group, COPD was confirmed in 32.9% of
cases, while 21.4% exhibited COPD of GOLD stage II. In
the high-risk group, COPD was present in 62.2% of patients,
while 48.1% had GOLD stage II COPD, and 14.9% had
severe or very severe COPD (GOLD stages III or IV).
Fig. 2A shows the GOLD stage distribution according to
age. The patient questionnaire categorized age according
to decades, with the highest category containing all
patients aged 70 years. Both COPD prevalence and
severity significantly increased with age category (P< 0.001
and P< 0.01, respectively). While among patients <50
years of age 36.6% had confirmed COPD, this fraction
increased to 60.6% among patients aged 70 years. The
fraction of patients with at least moderate COPD (GOLD
Table 2 Demographic and biometric data.
Gender Male Female
Validation (n (%)) 670 (61.6) 407 (37.4)
Screening (n (%)) 7760 (60.0) 4786 (37.0)
Age (yrs) 40e49 50e59 60e69 70
Validation (n (%)) 254 (23.3) 340 (31.3) 299 (27.5) 193 (17.7)
Screening (n (%)) 3438 (26.6) 4114 (31.8) 3496 (27.0) 1852 (14.3)
Body mass index <25.4 25.4e29.7 >29.7
Validation (n (%)) 434 (39.9) 377 (34.7) 275 (25.3)
Screening (n (%)) 5488 (42.4) 4801 (37.1) 2541 (19.6)
Smoking history (pack-years) 14 15e24 25e49 50
Validation (n (%)) 247 (22.7) 221 (20.3) 430 (39.5) 190 (17.5)
Screening (n (%)) 2883 (22.3) 3037 (23.5) 5153 (39.8) 1862 (14.4)
Lung function FEV1 (L) FEV1
(% of standard value)
FEV1/FVC (%)
Validation mean S.D. 2.42 0.87 80.43 22.24 82.51 18.35
Practice-based COPD screening 1015stage II) more than doubled from 22.4% to 49.2%, and that
of patients with severe or very severe COPD (GOLD stages III
or IV) increased 4-fold between age <50 years and 70
years, respectively. COPD prevalence and severity also
significantly (P< 0.0001) depended on the number of pack-
years of cigarettes smoked (Fig. 2B). Having smoked at
least 50 pack-years of cigarettes increased the probability
of being diagnosed with COPD of any severity, of at least
moderate COPD, or of COPD in the severe or very severe
stages by 40.5%, 59.1%, and 250%, respectively, compared
with having smoked less than 15 pack-years of cigarettes.0% 
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Figure 1 Distribution of COPD prevalence and GOLD stages in
the entire validation population (left column, nZ 1088) as well
as stratified according to COPD risk category, as derived from
the 10-item questionnaire (right columns: low (nZ 359),
intermediate (nZ 361), and high (nZ 362) COPD risk score).
Segments of each column show the percentages of patients
within GOLD stages for the respective population. Both COPD
prevalence and severity significantly increased with risk score
category. Patients with excluded COPD and those awaiting
further clarification were pooled into one group (no confirmed
COPD).Low body mass index was associated with a significantly
higher overall prevalence of COPD (51.4% for a BMI< 25.4 vs
41.8% for a BMI> 29.7; P< 0.05). This difference could
entirely be ascribed to a 4.7-fold increase in the fraction of
patients being in COPD stages III or IV while the prevalence
of stage I and stage II disease was similar between the three
BMI categories (Fig. 2C). Table 3 shows COPD prevalence
and GOLD stage distribution according to the remaining
questionnaire items. The prevalence of COPD did not
significantly differ between patients with and without
a history of allergy (PZ 0.082). In contrast, COPD preva-
lence was significantly associated with wheezing
(P< 0.001), suffering from cough affected by weather
conditions (P< 0.01), coughing up sputum in the morning
(P< 0.001), and coughing up sputum even in the absence of
a cold (P< 0.001), compared to patients that did not
complain about the respective symptoms.
In order to test whether the population of patients
examined in this study was representative for a primary
care practice population, we separately assessed an addi-
tional 12,935 patients who filled in patient questionnaires
without being validated by pulmonologists. These patients
were comparable to the population evaluated here
(nZ 1.088) with regard to all recorded demographic and
biometric data as well as questionnaire-derived COPD risk
score (data not shown).
Discussion
Due to the progressive nature of COPD, any delay in diag-
nosing a patient may result in irreversible loss of lung
function. Therefore, the American Thoracic Society (ATS)
and the European Respiratory Society (ERS) issued a posi-
tion paper11 in order to raise awareness of COPD, foster
early diagnosis and promote the concept that COPD is
a treatable disease. Unfortunately, early diagnosis of COPD
is impeded by the fact that significant airflow obstruction
may be present before the individual itself becomes aware
of it.3 Accordingly, as many as one half of subjects identi-
fied in large cross-sectional population studies to be
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Figure 2 COPD prevalence and GOLD stage distribution
according to individual items of the questionnaire. A: age. B:
smoking history. C: body mass index. Segments of each column
show the percentages of patients within GOLD stages for the
respective patient group. COPD prevalence and severity
significantly increased with both age (panel A) and extent of
cigarette smoke exposure (pack-years, panel B). BMI showed
an inverse relationship with the fraction of patients with
severe or very severe COPD (GOLD III/IV, panel C). Patients
with excluded COPD and those awaiting further clarification
were pooled into one group (no confirmed COPD).
1016 H. Ko¨gler et al.affected by COPD had no previous diagnosis of lung
disease.5,6 These studies demonstrated that population-
based screening programmes are effective in uncovering
COPD in previously undiagnosed patients. However, in the
absence of any preselection of patients at an increased risk
to be affected by COPD, a large number of patients have to
be screened using spirometry in order to identify COPDcases. Furthermore, among those identified, cases of mild
COPD predominate, in which evidence regarding benefit
from therapeutic intervention is sparse, since clinical trials
usually include patients with more advanced COPD
stages.12
In the current case-finding study, we used two easily
applied screening questions (regarding smoking status and
the presence of cough and/or dyspnea) to select patients
from a representative primary care practice population
aged 40 years, for referral to a pulmonologist in order to
confirm or rule out a diagnosis of COPD. In this preselected
group of patients, the NNS to identify a case of COPD was
2.1, while 2.9 patients had to be evaluated to find a case of
at least moderate COPD, corresponding to GOLD stage II.
These numbers are substantially lower than those observed
in the German subpopulation of the BOLD study,2,8 in which
the NNS within an unselected population of either gender
and aged 40 years were 8 or 18 to identify one case with
COPD or at least GOLD II COPD, respectively. Thus, these
two simple questions greatly improve the ratio of spirom-
etries carried out to COPD cases identified and thus the
cost-effectiveness of case finding.
Our use of the 10-item questionnaire9 allowed us to
subdivide the validation population into three risk cate-
gories that were found to have lower, intermediate, and
higher COPD prevalence, respectively. However, within this
population of high overall prevalence of COPD, the addi-
tional benefit of using the questionnaire was limited: if the
presumed low-risk category had been excluded from
spirometry evaluation, as many as 23% (118/516) of the
patients affected by COPD would have been missed within
the validation population. Therefore, arbitrarily selecting
a cut-off questionnaire-derived risk score value to exclude
patients from diagnostic testing appears to be inappro-
priate within such a preselected patient population.
A recent report13 likewise has raised doubt in the usefulness
of this 10-item questionnaire as a diagnostic tool in a pre-
selected population of patients with a high risk for airway
disease.
Nevertheless, analyzing the individual items of the
questionnaire yielded relevant findings: even in this pre-
selected population of symptomatic current or ex-smokers,
the prevalence and severity of COPD still strongly depended
on the number of pack-years of cigarettes smoked as well
as on age. A low body mass index particularly was associ-
ated with a higher prevalence of stage III/IV COPD, indi-
cating that COPD patients with weight loss may be at an
increased risk of rapidly progressing to advanced disease
states. Finally, the COPD prevalence in patients with or
without a history of allergy did not significantly differ.
Therefore, physicians should not disregard the possibility
that COPD may be the underlying cause when a patient 40
years of age with a history of allergy who is a smoker or ex-
smoker complains about chronic or repeated respiratory
symptoms.
Early diagnosis is important for COPD patients: diag-
nosing COPD in current smokers has been shown to increase
both the willingness to quit smoking and the success rate of
smoking cessation programmes,14e16 offering the potential
for slowing the progression of the disease.4 The clinical
relevance of screening for patients with GOLD stage-I COPD
has recently been questioned,17 since many of these
Table 3 COPD prevalence and GOLD stage distribution according to questionnaire variables.
No COPD (n (%)) Confirmed COPD (n (%)) GOLD I (n (%)) GOLD II (n (%)) GOLD III/IV (n (%))
Allergy
Yes (nZ 210) 121 (57.6) 89 (42.4) 20 (9.52) 62 (29.5) 7 (3.3)
No (nZ 869) 444 (51.1) 425 (48.9) 116 (13.4) 227 (26.1) 82 (9.44)
Wheezing
Yes (nZ 729) 337 (46.2) 392 (53.8) 99 (12.4) 217 (29.8) 76 (10.3)
No (nZ 354) 232 (65.5) 122 (34.5) 38 (10.7) 71 (20.1) 13 (3.7)
Cough affected
by weather
Yes (nZ 395) 182 (46.1) 213 (53.9) 46 (12.9) 113 (28.6) 49 (12.4)
No (nZ 615) 342 (55.6) 273 (44.4) 71 (12.5) 160 (26.0) 36 (5.9)
Sputum in the morning
Yes (nZ 537) 252 (46.9) 285 (53.1) 63 (11.7) 159 (29.6) 63 (11.7)
No (nZ 543) 314 (57.8) 229 (42.2) 73 (13.4) 131 (24.1) 25 (4.6)
Sputum in the absence of a cold
Yes (nZ 768) 369 (48.1) 399 (51.9) 105 (13.7) 221 (28.8) 73 (9.5)
No (nZ 318) 203 (63.8) 115 (36.2) 32 (10.1) 67 (21.1) 16 (5.0)
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may, however, only apply to non-symptomatic patients. It
should be emphasized that the two entry questions used in
this study to screen consecutive patients preselected
smokers or ex-smokers that were symptomatic. In a recent
report, symptomatic patients with GOLD-I COPD treated
with a bronchodilator experienced reduced levels of dysp-
nea upon exercising.18 This group of patients will be denied
such a benefit as long as they are not noticed by the doctor.
Interestingly, in the German subpopulation within the BOLD
study, stage I comprised 55% of all patients diagnosed with
COPD,2,8 while in our current study patients with GOLD-I
COPD represent only 27% of all subjects with a pulmonary
specialist-confirmed diagnosis of COPD. The fact that the
two screening questions in the current study led to exclu-
sion of non-symptomatic patients most likely explains
a substantial part of this striking difference.
Identification of patients with COPD of GOLD stage II
should receive particular attention: maintenance treat-
ment according to guideline recommendations can only be
initiated following diagnosis of COPD and several treatment
options are available that have been shown to reduce the
occurrence of exacerbations and improve the quality of
life. Diagnosed COPD patients with an intercurring respi-
ratory infection will benefit from being treated for an acute
exacerbation of COPD, rather than acute bronchitis.19
The benefit from early diagnosis extends beyond the
affected patients: COPD screening exhibits a favorable
cost-effectiveness ratio.20 One of the key parameters for
calculations of the cost-effectiveness for screening is the
COPD prevalence in the population to be screened. Thus,
reducing the NNS e such as by applying the two simple
questions evaluated in this investigation e will further
enhance the cost-effectiveness of COPD screening.
Healthcare costs are several-fold more expensive for
patients with severe COPD than for patients with mild
COPD.21,22 By slowing the progression of the disease (e.g.,
due to smoking cessation), patients will remain in milderstages for longer, thereby reducing the costs.20 Since the
severity of airflow obstruction is inversely related to
participation in the work force,23 slowing the progression of
the disease will keep patients in the workforce for longer,
causing a reduction in indirect cost of COPD for the society,
which exceeds the direct cost of the disease.24
This investigation was conducted in a real-life environ-
ment of established community healthcare conditions
among pulmonologists and locally associated primary care
physicians. Several aspects of such a study design may be
seen as limitations:
(1) The criteria for diagnosing COPD were left at the
discretion of the individual pulmonologists (although
they were instructed to follow GOLD recommendations
for diagnosis and severity staging), with no external
quality control. This may have resulted in some inac-
curacy of diagnoses. On the other hand, these COPD
diagnoses potentially reflect the numbers usually seen
by healthcare providers and health insurance compa-
nies more accurately than if they had been generated
with a strenuous external quality control.
(2) The drop-out rate of patients screened by their PCPs
but not showing up for evaluation by the pulmonologist
was substantial, which may have created bias: patients
with more severe respiratory symptoms may have
a stronger incentive to follow their PCP’s recommen-
dation of consulting with a specialist, bearing the
potential of overestimating COPD prevalence and
severity within the population. However, this pop-
ulation was similar with regards to demographic and
biometric data and COPD risk score, to a separate
population of 12,935 patients who were screened in
parallel without follow-up for diagnostic confirmation
(data not shown). Thus, a self-selection of more
severely affected patients among the validation pop-
ulation is not likely to have occurred. Our observation
of such a high drop-out emphasizes that PCPs need to
1018 H. Ko¨gler et al.thoroughly follow-up with their patients when they
suspect respiratory disease and make a referral for
consultation with a specialist.
(3) Patients not answering the two screening questions
with ‘‘yes’’ were not evaluated. Therefore, no infor-
mation is available on how many COPD patients within
the background population were missed because they
either never smoked or did not complain of respiratory
symptoms. However, a large part of COPD diagnoses
missed in non-smoking patients would encompass mild
stages of the disease, while most of the patients with
more severe COPD, who have the most urgent need to
intervene medically, can be detected by the screening
employed in this study. Current smokers with respira-
tory symptoms represent the patient subgroup that can
gain the greatest benefit from early COPD diagnosis by
being motivated to quit smoking.4 Also, no formal
assessment of the specificity of the two screening
criteria (current or previous smoker; suffering from
cough and/or breathlessness) for predicting a COPD
diagnosis was carried out. Breathlessness may be
experienced by patients affected by heart disease or
even healthy people if poorly trained. Cough may, e.g.,
be caused by gastro-esophageal reflux or chronic lower
airway inflammation without obstruction. This may
explain why in this study in about 50% of subjects no
diagnosis of COPD was found.
In conclusion, this investigation demonstrates that use
of the two simple screening questions regarding smoking
status and respiratory symptoms enables PCPs to preselect
among their practice population a group of patients with
a substantially increased risk of COPD. The extent of under-
diagnosis of COPD that has been observed in many countries
could greatly be reduced if PCPs consistently asked these
questions to every patient 40 years of age visiting their
practice and enforced diagnostic clarification in those
patients answering both of these questions with ‘‘yes’’.
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